Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Senores Pharmaceuticals will attend a group investor meeting hosted by Macquarie on June 09, 2026. The meeting will be held physically in Mumbai and focus on publicly available information.
Jun 04 2026 15:48:31
Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Senores Pharmaceuticals will attend an analyst and institutional investor meeting hosted by Ambit Capital on May 25, 2026. Discussions will cover publicly available information.
May 20 2026 11:20:52
Senores Pharmaceuticals Ltd - 544319 - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On March 31, 2026
Senores Pharma provided an update on the utilization of its Rs. 500 crore IPO funds. A Rs. 33.02 crore capex for its subsidiary, Havix, is delayed to FY27 due to geopolitical issues. Additionally, Rs. 6.31 crore from offer expenses and Rs. 0.40 crore from debt repayment were re-allocated to general corporate purposes and inorganic growth.
May 14 2026 15:59:40
Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Senores Pharmaceuticals' Q4 FY26 Monitoring Agency Report highlights delays in deploying IPO proceeds. Significant delays include Rs. 33.02 cr for a manufacturing facility, now extended to FY27, and working capital investments. Funds have been re-allocated between various objectives.
May 14 2026 15:27:28
Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Senores Pharmaceuticals released its Q4 and FY26 financial results via a media release, reporting strong performance. Q4 total income increased by 66% to Rs.190 crore and PAT rose 104% to Rs.37 crore. The company also announced strategic acquisitions of Zoraya and Apnar Pharmaceuticals, and a new joint venture in the U.S. Federal Market.
May 14 2026 14:31:21
Senores Pharmaceuticals Ltd - 544319 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 14, 2026
Senores Pharma announced strong Q4 FY26 and full-year FY26 consolidated financial results. Q4 total income grew 66% to ₹190 Cr, EBITDA surged 219% to ₹62 Cr, and PAT increased 104% to ₹37 Cr. The company completed 75% stake acquisition in Apnar Pharmaceuticals and formed a 70% JV, Amerisyn, for the US federal market.
May 14 2026 14:13:34
Read More